Copyright ©The Author(s) 2015.
World J Exp Med. May 20, 2015; 5(2): 124-129
Published online May 20, 2015. doi: 10.5493/wjem.v5.i2.124
Table 1 Suggested guidelines for biochemical and instrumental surveillance screenings in individuals bearing any MEN1 gene mutation
Tumour/lesionRecommended age of begin screenings (yr)Biochemical screeningsFrequencyInstrumental screeningsFrequency
Parathyroid adenoma8Fasting total serum calcium concentration (corrected for albumin) and/or ionized-serum calcium concentrationYearlyNoneNA
Fasting serum concentration of full-length PTH
Gastrinoma20Fasting serum gastrin concentrationYearlyNoneNA
Insulinoma5Fasting serum glucose and insulin concentrationYearlyNoneNA
Other pancreatic neuroendocrine tumoursUnder 10Serum concentration of chromogranin-A, glucagone, pancreatic polypeptide, vasoactive intestinal peptideYearlyAbdominal CT, MRI or EUSYearly
Anterior pituitary adenoma5Serum concentration of prolactin and insulin-like growth factor-1YearlyHead MRIEvery 3-5 yr (depending on results of biochemical screenings)
Adrenal gland tumourUnder 10None unless symptoms or signs of functioning tumour and/or tumour > 1 cm are recognised by imagingNAAbdominal CT or MRIYearly with pancreatic imaging
Thymic and bronchial carcinoid15NoneNAThoracic CT or MRIEvery 1-2 yr